News

Leifras Co. Targets US IPO On Slowing Growth And Low Margins (LFS)

1 Mins read

This article was written by

Donovan Jones is a research specialist with 15 years of experience identifying opportunities for IPOs and public software companies.

He also leads the investing group IPO Edge, which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle – from filing to listing to quiet period and lockup expiration dates.

Learn more

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Read the full article here

Related posts
News

ZTR: Hybrid Portfolio With Utility Tilt At A Deep Discount (NYSE:ZTR)

1 Mins read
This article was written by Follow Nick Ackerman is a former financial advisor using his experience to provide coverage on closed-end funds…
News

IJT ETF: Why The Tide May Turn For Small-Cap Growth In 2026 (NASDAQ:IJT)

1 Mins read
This article was written by Follow The Sunday Investor is focused exclusively on U.S. Equity ETFs. He has a strong analytical background,…
News

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

1 Mins read
Follow Play Earnings CallPlay Earnings Call Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *